Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
May 12, 2020: Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
May 12, 2020: Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy
April 28, 2020: Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team